Aeolus reports positive safety results from Phase 1 study of AEOL 10150 in ALS patients

Aeolus Pharmaceuticals, a San Diego-based company working on CNS diseases, announced results for its multi-center, double-blind, randomized, placebo-controlled, Phase 1 clinical trial of AEOL 10150 in ALS patients. “We are very pleased with the results from our Phase 1 single dose study of AEOL 10150 and we are looking forward to moving this exciting and potential therapeutic into multiple dose evaluation,” said Aeolus CEO Richard P. Burgoon, Jr. in a PR Newswire release. Mr. Burgoon also noted that although the Phase 1 single and multiple dose studies are being conducted in ALS patients, safety studies can also support human efficacy studies in other clinical indications for which AEOL 10150 has shown pre-clinical efficacy.

Click here to read more.

Share this: